Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer

Sang Joon Shin, Hei Cheul Jeung, Joong Bae Ahn, Sun Young Rha, Nae Choon Yoo, Jae Kyung Roh, Sung Hoon Noh, Hyun Cheol Chung

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We investigated whether the level of bone marrow-derived progenitor cells and mature endothelial cells could be used as predictors of clinical outcome in patients receiving taxotere-based chemotherapy for advanced gastric cancer. Peripheral blood mononuclear cells were obtained from 49 gastric cancer patients who received taxotere combined with 5-FU and leucovorin and prophylactic G-CSF treatment. To categorize the cells, the cell markers CD34, vWF, P1H12, and CD31 were stained. Changes in these cells were examined before and after chemotherapy, and the clinical significance of these changes to response prediction and prognosis were investigated. Before the second cycle of chemotherapy, the number of CD34+/vWF+ and CD34+ cells was higher in non-responders as compared to the responders. Patients with ≥6.2 CD34+/vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with <6.2 CD34+/vWF+/ml (6.0 months, p = 0.076). Patients with ≥5.8 CD34+ cells/ml had shorter progression free survival (4.0 months) than patients with <5.8 CD34+ cells/ml (6.1 months, p = 0.046). In an ex vivo pharmacokinetic study, the maximum inhibition (Imax) for HUVEC and YCC3 cells was 13.0 ± 6.6% and 74.0 ± 2.0%, respectively. The time to reach Imax (Tmax) was 72 h in all HUVEC cells and 0.5 hours in YCC3 cells. We suggested that CD34+/vWF+ and CD34+ cells can be used as a biomarker for prediction and CD34+ cells for prognosis.

Original languageEnglish
Pages (from-to)269-276
Number of pages8
JournalCancer Letters
Volume270
Issue number2
DOIs
Publication statusPublished - 2008 Nov 8

Fingerprint

Granulocyte Colony-Stimulating Factor
Stomach Neoplasms
Biomarkers
Drug Therapy
docetaxel
Human Umbilical Vein Endothelial Cells
Disease-Free Survival
Leucovorin
Fluorouracil
Blood Cells
Stem Cells
Endothelial Cells
Pharmacokinetics
Bone Marrow

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Shin, Sang Joon ; Jeung, Hei Cheul ; Ahn, Joong Bae ; Rha, Sun Young ; Yoo, Nae Choon ; Roh, Jae Kyung ; Noh, Sung Hoon ; Chung, Hyun Cheol. / Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. In: Cancer Letters. 2008 ; Vol. 270, No. 2. pp. 269-276.
@article{54ec46411a5e47da8ddfdaab9b0e09dd,
title = "Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer",
abstract = "We investigated whether the level of bone marrow-derived progenitor cells and mature endothelial cells could be used as predictors of clinical outcome in patients receiving taxotere-based chemotherapy for advanced gastric cancer. Peripheral blood mononuclear cells were obtained from 49 gastric cancer patients who received taxotere combined with 5-FU and leucovorin and prophylactic G-CSF treatment. To categorize the cells, the cell markers CD34, vWF, P1H12, and CD31 were stained. Changes in these cells were examined before and after chemotherapy, and the clinical significance of these changes to response prediction and prognosis were investigated. Before the second cycle of chemotherapy, the number of CD34+/vWF+ and CD34+ cells was higher in non-responders as compared to the responders. Patients with ≥6.2 CD34+/vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with <6.2 CD34+/vWF+/ml (6.0 months, p = 0.076). Patients with ≥5.8 CD34+ cells/ml had shorter progression free survival (4.0 months) than patients with <5.8 CD34+ cells/ml (6.1 months, p = 0.046). In an ex vivo pharmacokinetic study, the maximum inhibition (Imax) for HUVEC and YCC3 cells was 13.0 ± 6.6{\%} and 74.0 ± 2.0{\%}, respectively. The time to reach Imax (Tmax) was 72 h in all HUVEC cells and 0.5 hours in YCC3 cells. We suggested that CD34+/vWF+ and CD34+ cells can be used as a biomarker for prediction and CD34+ cells for prognosis.",
author = "Shin, {Sang Joon} and Jeung, {Hei Cheul} and Ahn, {Joong Bae} and Rha, {Sun Young} and Yoo, {Nae Choon} and Roh, {Jae Kyung} and Noh, {Sung Hoon} and Chung, {Hyun Cheol}",
year = "2008",
month = "11",
day = "8",
doi = "10.1016/j.canlet.2008.05.011",
language = "English",
volume = "270",
pages = "269--276",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. / Shin, Sang Joon; Jeung, Hei Cheul; Ahn, Joong Bae; Rha, Sun Young; Yoo, Nae Choon; Roh, Jae Kyung; Noh, Sung Hoon; Chung, Hyun Cheol.

In: Cancer Letters, Vol. 270, No. 2, 08.11.2008, p. 269-276.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer

AU - Shin, Sang Joon

AU - Jeung, Hei Cheul

AU - Ahn, Joong Bae

AU - Rha, Sun Young

AU - Yoo, Nae Choon

AU - Roh, Jae Kyung

AU - Noh, Sung Hoon

AU - Chung, Hyun Cheol

PY - 2008/11/8

Y1 - 2008/11/8

N2 - We investigated whether the level of bone marrow-derived progenitor cells and mature endothelial cells could be used as predictors of clinical outcome in patients receiving taxotere-based chemotherapy for advanced gastric cancer. Peripheral blood mononuclear cells were obtained from 49 gastric cancer patients who received taxotere combined with 5-FU and leucovorin and prophylactic G-CSF treatment. To categorize the cells, the cell markers CD34, vWF, P1H12, and CD31 were stained. Changes in these cells were examined before and after chemotherapy, and the clinical significance of these changes to response prediction and prognosis were investigated. Before the second cycle of chemotherapy, the number of CD34+/vWF+ and CD34+ cells was higher in non-responders as compared to the responders. Patients with ≥6.2 CD34+/vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with <6.2 CD34+/vWF+/ml (6.0 months, p = 0.076). Patients with ≥5.8 CD34+ cells/ml had shorter progression free survival (4.0 months) than patients with <5.8 CD34+ cells/ml (6.1 months, p = 0.046). In an ex vivo pharmacokinetic study, the maximum inhibition (Imax) for HUVEC and YCC3 cells was 13.0 ± 6.6% and 74.0 ± 2.0%, respectively. The time to reach Imax (Tmax) was 72 h in all HUVEC cells and 0.5 hours in YCC3 cells. We suggested that CD34+/vWF+ and CD34+ cells can be used as a biomarker for prediction and CD34+ cells for prognosis.

AB - We investigated whether the level of bone marrow-derived progenitor cells and mature endothelial cells could be used as predictors of clinical outcome in patients receiving taxotere-based chemotherapy for advanced gastric cancer. Peripheral blood mononuclear cells were obtained from 49 gastric cancer patients who received taxotere combined with 5-FU and leucovorin and prophylactic G-CSF treatment. To categorize the cells, the cell markers CD34, vWF, P1H12, and CD31 were stained. Changes in these cells were examined before and after chemotherapy, and the clinical significance of these changes to response prediction and prognosis were investigated. Before the second cycle of chemotherapy, the number of CD34+/vWF+ and CD34+ cells was higher in non-responders as compared to the responders. Patients with ≥6.2 CD34+/vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with <6.2 CD34+/vWF+/ml (6.0 months, p = 0.076). Patients with ≥5.8 CD34+ cells/ml had shorter progression free survival (4.0 months) than patients with <5.8 CD34+ cells/ml (6.1 months, p = 0.046). In an ex vivo pharmacokinetic study, the maximum inhibition (Imax) for HUVEC and YCC3 cells was 13.0 ± 6.6% and 74.0 ± 2.0%, respectively. The time to reach Imax (Tmax) was 72 h in all HUVEC cells and 0.5 hours in YCC3 cells. We suggested that CD34+/vWF+ and CD34+ cells can be used as a biomarker for prediction and CD34+ cells for prognosis.

UR - http://www.scopus.com/inward/record.url?scp=52449093276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52449093276&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2008.05.011

DO - 10.1016/j.canlet.2008.05.011

M3 - Article

C2 - 18555590

AN - SCOPUS:52449093276

VL - 270

SP - 269

EP - 276

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -